Occam Recruits Former FDA Commissioner to Faeth Therapeutics
In November 2024, Occam Global recruited Stephen M. Hahn, M.D., to the board of Faeth Therapeutics. Hahn is a CEO-Partner of Flagship Pioneering and Chief Executive Officer of Harbinger Health.
Steve brings two decades of illustrious leadership in healthcare strategy, oncology, and translational/clinical research to this role. From 2019 to 2021, he served as the 24th U.S. Food and Drug Administration (FDA) Commissioner, overseeing COVID and non-COVID regulatory affairs, including therapeutics and vaccine development, devices, diagnostics, and clinical trials.
Before his appointment to the FDA, Steve held the positions of Chief Medical Executive and Chief Operating Officer at the prestigious MD Anderson Cancer Center in Houston, Texas. Prior to his executive roles at MD Anderson, he also led the Perelman School of Medicine radiation oncology department at the University of Pennsylvania.
Steve earned his M.D. from Temple University and his B.A. in Biology from Rice University.
About Faeth Therapeutics
Faeth Therapeutics focuses on developing cancer treatments by targeting the unique metabolic dependencies of cancer cells. Using insights from computational biology and machine learning, they analyze the specific metabolic pathways that fuel tumor growth. This approach allows Faeth to design therapies that disrupt multiple key metabolic points within cancer cells, aiming to weaken or eliminate their ability to proliferate.
In addition to their scientific innovation, Faeth offers a patient-centric experience through their app, which helps patients adhere to treatment protocols by customizing their nutritional and metabolic support. Their clinical trials incorporate this targeted metabolic approach, providing patients with personalized guidance to maximize the effectiveness of these therapies. This approach represents a shift in oncology by addressing cancer metabolism as a means to improve treatment outcomes.
Explore how we’ve helped life science organizations build exceptional executive leadership through our case studies.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.